Skip to content
Cultural Foundation
Author:
Neuraxpharm; Minoryx Therapeutics
NEZGLYAL® (leriglitazone) receives a positive CHMP opinion for the treatment of cerebral Adrenoleukodystrophy (cALD), a rare neurodegenerative disease
July 24, 2026